Shopping Cart
Remove All
Your shopping cart is currently empty
WDR5-0102 is a compound that inhibits the WDR5-MLL1 interface (K dis = 7 μM, K d = 4 μM), selectively reducing MLL1 HMT activity without affecting the human H3K4 methyltransferase SETD7 or other HMTs, including G9a, EHMT1, SUV39H2, SETD8, PRMT3, and PRMT5.

| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 1 mg | $70 | In Stock | In Stock | |
| 5 mg | $172 | In Stock | In Stock | |
| 10 mg | $289 | In Stock | In Stock | |
| 25 mg | $578 | In Stock | In Stock | |
| 50 mg | $833 | In Stock | In Stock | |
| 100 mg | $1,150 | In Stock | In Stock | |
| 500 mg | $2,290 | - | In Stock | |
| 1 mL x 10 mM (in DMSO) | $226 | In Stock | In Stock |
| Description | WDR5-0102 is a compound that inhibits the WDR5-MLL1 interface (K dis = 7 μM, K d = 4 μM), selectively reducing MLL1 HMT activity without affecting the human H3K4 methyltransferase SETD7 or other HMTs, including G9a, EHMT1, SUV39H2, SETD8, PRMT3, and PRMT5. |
| Targets&IC50 | SHP2 (human):1.8 µM, WDR5-MLL1:4 μM(Kd), WDR5-MLL1:7 μM(Kdis) |
| In vitro | Bioassay-guided fractionation resulted in the isolation of Mauritianin as a new topoisomerase I inhibitor.[1] After 14 weeks, Mauritianin antagonized the flavonol glycosides on cell-mediated immunosuppression in the two-stage carcinogenesis in terms of initiation.[3] |
| Molecular Weight | 374.82 |
| Formula | C18H19ClN4O3 |
| Cas No. | 824960-50-1 |
| Smiles | N(C(=O)C1=C(Cl)C=CC=C1)C2=C(C=CC(N(=O)=O)=C2)N3CCN(C)CC3 |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. | |||||||||||||||||||||||||||||||||||
| Solubility Information | DMSO: 55 mg/mL (146.74 mM), Sonication is recommended. | |||||||||||||||||||||||||||||||||||
| In Vivo Formulation | 10% DMSO+40% PEG300+5% Tween 80+45% Saline: 1 mg/mL (2.67 mM), Sonication is recommended. Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions. | |||||||||||||||||||||||||||||||||||
Solution Preparation Table | ||||||||||||||||||||||||||||||||||||
DMSO
| ||||||||||||||||||||||||||||||||||||
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2025 TargetMol Chemicals Inc. All Rights Reserved.